56.3 F
New York
Tuesday, May 17, 2022

AstraZeneca’s [NASDAQ: AZN] Brazilian Volunteer In COVID-19 Vaccine Trial Reportedly Dead

Must read

Brazilian Volunteer in the coronavirus vaccine trial of AstraZeneca [NASDAQ: AZN] and Oxford University has died. Authorities of Brazil disclosed that the testing of the vaccine continues despite the death of the participant.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Brazilian Health Authority has confirmed the news and revealed that it had just got the information from an investigation into the death.

The volunteer identity hasn’t disclosed yet and it is not clear whether the person is died because of the vaccine or due to an unrelated pre-existing condition.

Share of AstraZeneca traded down 0.53% at $51.92 during the trading session of Wednesday. It had a trading volume of 6.2 million as compared to the average volume of 4.64 million.

In the past 52-weeks of trading, this company’s stock has changed between the 52-weeks low range of $36.15 and a high range of $64.94. It has moved up 43.61% from its 52-weeks low and moved down -20.06% from its 52-weeks high.

Looking at its liquidity, it has a current ratio of 0.80. AZN market capitalization has remained high, hitting $136.45 billion at the time of writing.

The Federal University of São Paulo confirmed the news that the volunteer was Brazilian. The Federal University of São Paulo is helping the coordinate Phase III trial in Brazil. Oxford representative also disclosed that they are no safety concerns regarding the usage of the vaccine candidate.

More articles

Latest article